The TIP-CA model provides a robust, evidence-based framework for predicting malignancy in adult patients diagnosed with dermatomyositis (DM) or clinically amyopathic dermatomyositis (CADM).
The model utilizes five routinely available clinical and serological factors: anti-TIF1-γ antibody status, presence of interstitial lung disease (ILD), poikiloderma, DM subtype, and anemia.
In both derivation and validation cohorts, the model demonstrated high discriminatory accuracy with an area under the curve (AUC) of approximately 0.81.
This tool enables clinicians to move beyond generalized screening toward a risk-stratified approach, potentially reducing diagnostic delays and improving survival rates.
Background: The Critical Link Between Dermatomyositis and Malignancy
